A new international study has found that combining two cancer medicines may significantly slow the growth of a dangerous form ...
Identification of variants influences treatment decisions. Inhibitors of the poly-ADP-ribose polymerase (PARP) system, a pathway for repairing single-stranded DNA breaks, are recommended for tumors ...
(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...
Germline testing can identify hereditary cancer, which leads to implications for family members, cascade testing for relatives, and starting surveillance and prevention measures: Genetic testing in ...
Lymphocyte Infiltration Score and Spatial Characteristics Refined the Prognosis and Denosumab Treatment Responsiveness Indicators for Giant Cell Tumor of Bone Outcomes data for DNA-damaging ...
A phase 1b/2 study evaluating the activity of tinengotinib in combination with androgen receptor pathway inhibitors (ARPIs) in patients with metastatic castration resistant prostate cancer (mCRPC). A ...
In today’s fast-paced world, maintaining prostate health has become increasingly challenging for men as they age. The importance of a healthy prostate cannot be overstated, as it plays a critical role ...
The 2026 European Association of Urology (EAU) annual meeting featured a PARP inhibitors for prostate cancer session and a presentation by Dr. Martin Gleave discussing how to optimize tissue biopsy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results